Phase 1 Trial of CAR-T Cell Therapy for Head and Neck Cancer

Share this content:
Researchers are evaluating whether patients with squamous cell cancer of the head and neck will respond to autologous T4+ positive T cells administered directly into the disease site.
Researchers are evaluating whether patients with squamous cell cancer of the head and neck will respond to autologous T4+ positive T cells administered directly into the disease site.

Title: Phase I Trial: T4 Immunotherapy of Head and Neck Cancer1

Principal Investigators: John Maher, MD PhD, King's College London

Description: For this single-arm, phase 1 study (ClinicalTrials.gov Identifier: NCT01818323), researchers are evaluating whether patients with squamous cell cancer of the head and neck will respond to autologous T4+ positive T cells administered directly into the disease site.

The T4+ T cells will express T1E28z, a chimeric antigen receptor (CAR).

To qualify patients must have locally advanced or recurrent/metastatic disease not suitable for further standard treatment.

The primary outcomes are dose-limiting toxicities and determination of an optimal dose for a phase 2 trial. Secondary outcomes include serum cytokine levels post-treatment, persistence of T4+ T cells at disease site, and preliminary assessment of drug efficacy.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT01818323.

Status: This study is open and recruiting participants as of May 9, 2017.

This study is sponsored by King's College London in collaboration with Guy's and St Thomas' National Health Service (NHS) Trust.

Reference

  1. Clinicaltrials.gov. Phase I trial: T4 immunotherapy of head and neck cancer. NCT01818323. https://clinicaltrials.gov/ct2/show/NCT01818323. Accessed May 9, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters